RKN containers market seen growing to $2.6 billion by 2030

The market for RKN containers, used to move temperature-sensitive pharmaceuticals and biologics by air, is projected to rise from $1.55 billion in 2025 to $2.6 billion by 2030. Growth is being fueled by biologics production, cold-chain investment and tighter requirements for safe pharmaceutical transport.

Why it matters: - RKN containers are a critical part of pharmaceutical air freight because they help protect product quality, safety and regulatory compliance. - Demand is rising as more drugs, vaccines and biologics need validated temperature control during long-distance transport. - The market’s growth signals continued investment in cold-chain infrastructure and specialized air cargo capacity.

What happened: - The RKN containers market is projected to grow from $1.55 billion in 2025 to $1.72 billion in 2026. - The 2025-2026 increase implies an 11.3% CAGR. - The market is forecast to reach $2.6 billion by 2030. - The forecast period through 2030 implies a 10.9% CAGR. - The analysis appears in The Business Research Company’s RKN Containers Global Market Report 2026. - The report was released Sept. 24, 2026, from London.

The details: - RKN containers are specialized temperature-controlled air cargo containers mainly used for pharmaceuticals and biologics. - The market’s recent growth has been driven by rising global pharmaceutical exports and stronger demand for temperature-sensitive transport. - Biologics and vaccine distribution networks are expanding, adding more demand for insulated air cargo solutions. - Stricter rules for safe pharmaceutical transport are also supporting adoption. - Future growth is expected to come from personalized medicine logistics, modernization of pharmaceutical supply chains and expansion of biologics manufacturing. - Other expected trends include validated cold-chain transportation technologies, longer temperature-preservation methods, stronger product-integrity controls and multi-temperature transport capabilities. - RKN containers are also used for perishable items. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The biggest driver is the rapid rise in biologics production, which increases the need for tightly controlled transport. - Biologics are highly temperature-sensitive, so transport failures can compromise efficacy. - The report cites US FDA authorization of 17 biologic therapies in 2023, equal to about 31% of the 55 drug approvals that year. - That approval mix underscores how quickly biologics are becoming a larger share of drug development. - Cold-chain spending is also expanding, which helps specialized containers fit into a larger logistics network. - The Global Cold Chain Alliance reported temperature-controlled warehouse capacity expanded by more than 600 million cubic feet in April 2024 versus 2023. - That expansion suggests the infrastructure needed to support RKN container use is scaling alongside demand.

What's next: - The market is likely to keep expanding as pharmaceutical manufacturers add biologics capacity and update supply chains. - Demand should continue to track investments in cold-chain logistics, airport handling and secure air cargo systems. - Asia-Pacific’s growth may narrow the gap with North America if manufacturing and logistics investments continue at the current pace. - The full report and sample request are available through The Business Research Company’s market report page and report listing.

The bottom line: - RKN containers are moving from niche logistics equipment to a growing requirement for global pharma and biologics shipping.